|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2001-3-19
|
|
pubmed:abstractText |
After standard therapy for advanced head and neck carcinoma, 5-year survival rate is less than 50%. Our purpose was to develop a new treatment for advanced head and neck carcinoma by using preoperative chemotherapy. Long term efficacy and toxicity of induction paclitaxel and carboplatin is reported here.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2001 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
91
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
940-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11251945-Adult,
pubmed-meshheading:11251945-Aged,
pubmed-meshheading:11251945-Aged, 80 and over,
pubmed-meshheading:11251945-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11251945-Carboplatin,
pubmed-meshheading:11251945-Carcinoma, Squamous Cell,
pubmed-meshheading:11251945-Disease-Free Survival,
pubmed-meshheading:11251945-Female,
pubmed-meshheading:11251945-Head and Neck Neoplasms,
pubmed-meshheading:11251945-Humans,
pubmed-meshheading:11251945-Male,
pubmed-meshheading:11251945-Middle Aged,
pubmed-meshheading:11251945-Paclitaxel,
pubmed-meshheading:11251945-Prognosis,
pubmed-meshheading:11251945-Treatment Outcome
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Induction paclitaxel and carboplatin for patients with head and neck carcinoma. Analysis of 62 patients treated between 1994 an 1999.
|
|
pubmed:affiliation |
Department of Internal Medicine, Division of Hematology and Oncology, Saint Louis University Health Sciences Center, St. Louis, Missouri 63110-0250, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
